Published in final edited form as:

Trends Microbiol. 2019 July ; 27(7): 593–606. doi:10.1016/j.tim.2019.02.009.

The Promise of Long Acting Antiretroviral Therapies: From Need to Manufacture

Howard E. Gendelman[#], JoEllyn McMillan[#], Aditya Bade[#], Benson Edagwa[#], and Bhavesh Kevadiya[#]

Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5880

[#] These authors contributed equally to this work.

Abstract

Antiretroviral therapy has transformed human immunodeficiency virus infections from certain death to a manageable chronic disease. Achieving strict adherence to drug regimens that limit toxicities and viral resistance are achievable goals. Success is defined by halting viral transmission and by continuous viral restriction. A step towards improving treatment outcomes is in long acting antiretrovirals. While early results remain encouraging there remain opportunities for improvement. These rest, in part, on the required large drug dosing volumes, local injection site reactions and frequency of injections. Thus, implantable devices and long acting parenteral prodrugs have emerged which may provide more effective clinical outcomes. The recent successes in transforming native antiretrovirals into lipophilic and hydrophobic prodrugs stabilized into biocompatible surfactants can positively affect both. Formulating antiretroviral prodrugs demonstrate improvements in cell and tissue targeting, in drug dosing intervals and in the administered volumes of nanosuspensions. As such the newer formulations also hold the potential to suppress viral loads beyond more conventional therapies with the ultimate goal of HIV-1 elimination when combined with other modalities.

Keywords

Long acting slow effective release antiretroviral therapy; regimen adherence; human immunodeficiency virus type one; viral reservoirs; good manufacturing practices; implantable devices

Current Long Acting (LA) Antiretroviral Drug (ARV) Formulations

Oral administration of antiretroviral (ARV) drugs is the major delivery route for treatment and prevention of human immunodeficiency virus type one (HIV-1) infection. While oral

Address reprints and correspondence to: Dr. Howard E. Gendelman, Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5880; fax 402 559 3733; phone 402 559 8920 and hegendel@unmc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

delivery focuses on aqueous drug solubility [1], LA hydrophobic ARV formulations affect bioavailability and pharmacokinetics (PK) [2–4]. The latter serves to improve regimen adherence and reduce viral drug resistance [5, 6]. To this end, in August 2018, ViiV Healthcare announced results from their phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study ([clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02951052) identifier: NCT02951052) where two long-acting drugs, cabotegravir (CAB) and rilpivirine (RPV) were used for treatment of chronic HIV-1 infection [3, 7]. The results of this once-a-month LA injectable paralleled the standard of care daily oral three-drug regimensⁱ. The ATLAS study entered infected adult patients who had previously maintained viral suppression for greater than six months on daily oral regimens (comprised of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent). Rates of viral suppression were equivalent between a continued three-drug oral therapy or after switching to the long acting, two-drug injectable CAB/RPV regimen. Moreover, the safety and drug resistance profiles were also consistent with results obtained from both Long-Acting Antiretroviral Treatment Enabling LATTE-1,2 regimens [2, 8]. Thus, the era of LA ARVs has begun. The questions now emerging are which platform, what drug combination, what dosing interval, ease of manufacture, stability and use will be realized as clinical regimens for prevention, treatment and transmission of viral infections. This review serves to outline each of these and provide a platform for discussion of the current and future directives of these new treatment regimens with the eye of how they can and would be used in therapeutic regimens designed to combat HIV-1 infections.

Chemical Approaches to Facilitate LA ARV Development

With LA ARVs in hand the question is now what comes next? One answer is the simple encapsulation of existing ARVs into nanoparticles [5, 7, 9–14] and the second is chemical drug modifications to produce hydrophobic prodrug nanocrystals [15–19]. The former requires sequential high-volume injections. The prodrug approach has the advantage of controlled hydrolysis, lipophilicity and avid mononuclear phagocyte (MP; monocyte and macrophage) depot formation [19, 20]. Success in extending the apparent drug half-life from hours to weeks or months was achieved with dolutegravir, cabotegravir, abacavir and lamivudine (DTG, CAB, ABC and 3TC) [16–19, 21–23]. Each has the added advantage of producing sustained native drug levels in blood, lymph nodes, spleen, brain, the genitourinary system and gut. Defined chemical modification ensures that each of the prodrugs can be simply and stably manufactured [18, 21, 22, 24]. Notably, improvements in prodrug particle uptake, retention, release and antiretroviral potency was achieved [16–19, 23]. Chemical characterization using nuclear magnetic resonance, X-ray diffraction and Fourier-transform infrared spectroscopies and mass spectrometry are the benchmarks for developing modified prodrugs. These enable physicochemical characterizations that are compared against water and octanol solubility, acidic and basic pH stability and prodrug pro-moiety cleavage to yield active drugs. Particle size, zeta potential, stability and intracellular distribution can predict activity after lyophilization and resuspension. Cell-based retention of drug particles can predict PK profiles.

ⁱ<https://www.viivhealthcare.com/en-gb/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/>

While CAB and RPV in their native active forms are hydrophobic, chemical modifications afford further improvements in their LA profiles. Historically, the hydrophobic properties of both facilitated their developments as aqueous nanosuspensions. CAB LA, a potent integrase strand transfer inhibitor designed as a dissolution-controlled depot ARV formulation, possesses a unique resistance profile with low aqueous solubility [9, 10]. When placed in an aqueous 200 mg/mL nanosuspension in polysorbate 20, polyethylene glycol 3350 and mannitol it demonstrates a long half-life [25]. Likewise, RPV LA is stabilized by poloxamer 338 with drug concentrations of 300 mg/mL in aqueous suspensions [4]. Intramuscular administration of both CAB and RPV LA forms depots at the injection site resulting in sustained drug release and circulation times [26]. RPV LA, which affords a weak barrier to resistance, requires refrigeration and light protection. Both CAB and RPV LAs are manufactured by top down wet milling techniques resulting in particle sizes of 200 nm sterilized by gamma irradiation. CAB and RPV LA are administered at 800 and 1200 mg doses, respectively, as 2 mL gluteal injections [27]. Thus, a significant use limitation rests in the high dosing volume requirement and resultant injection site reactions. These limitations together with limited formulation access to “putative” cell and tissue viral reservoirs open up opportunities for improvements [2, 18, 28]. The means to further reduce injection volumes while extending dosing intervals are active areas of research.

Implantables

Not mutually exclusive to the use of LA ARVs are implantables. These are placed subcutaneously to provide sustained ARV release [29–31]. Most contain polymeric matrices or rate limiting semipermeable membranes. One recent entry is a non-erodible silicone system loaded with tenofovir alafenamide (TAF) [31] fabricated from a silicone tubing with axial holes coated with a polyvinyl alcohol polymer membrane matrix to control drug release. The device demonstrated a sustained release profile over 40 days in dogs. It is removable and as such can protect against adverse reactions. However, surgical insertion and removal of the implant is a noted limitation in resource-limited settings.

Another example is a drug-eluting implant. This was used to provide prolonged release of 4'-ethynyl-2'-fluoro-2'-deoxyadenosine (MK-8591) [29]; a potent investigational nucleoside reverse transcriptase translocation inhibitor developed by Merck [32]. The device was fabricated from polylactic acid, polycaprolactone and polyethylene vinyl acetate biodegradable polymers using hot melt extrusion. The implants achieved sustained drug release at therapeutic concentrations for up to six months. While the device is promising, drug release itself must be optimized to ensure safety and efficacy prior to its use.

Vaginal rings, well known for their use as birth control devices, are also being evaluated for extended ARV release [33–38]. Drugs used in rings are stabilized in either polymeric matrices or cores [33, 34, 36, 39]. For example, a silicone ring incorporating dapivirine (DPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was recently developed [40, 41]. The ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) study in Phase 3 testing investigated the efficacy of a DPV-containing a vaginal ring compared to placebo in preventing HIV-1 infection [38]. The study enrolled 18–45 year-old African women at risk for HIV-1 infection. A silicone elastomer matrix drug ring was inserted once

every 4 weeks in 2629 women. HIV-1 infection occurred in 71 women in the group that received DPV compared with 97 in the placebo group, yielding HIV-1 incidences of 3.3 and 4.5 per 100 person-years. The incidence of HIV-1 infection in the DPV group was lower by 27% ($P = 0.046$). A higher rate of protection was observed among women over the age of 21 years but not in younger participants. The differences correlated with reduced adherence in younger women. Safety assessment, PK and acceptability of the DPV vaginal ring [37] confirmed its therapeutic potential. DPV plasma levels were also comparable in all enrolled women.

Subdermal implants can maintain plasma ARV drug concentrations at effective levels for more than a year [30]. A principal advantage of implants is consistent and predictable drug release serving to improve adherence and lower viral transmission. These were used to deliver TAF [31], nevirapine [30] and MK-8591 [29]. TAF implants were generated by loading drug powder into platinum cured microperforated silicone tubing. PK and safety parameters were tested in dogs for 40 days following subcutaneous insertion. The implants maintained sustained high concentrations of the pharmacologically active ARV metabolites. After a subcutaneous administration, sustained drug release was achieved at clinically relevant plasma drug concentrations [29]. Such subdermal implants have the potential to transform current daily ARVs to once a year.

An alternative to removable implants are biodegradable drug polymer devices. These are being developed with solid ARV polymer gels to deliver DTG for up to 9 months [42]. In this report the gel was fabricated from polylactic-*co*-glycolic acid and N-methyl-2-pyrrolidone in a solution of drug dissolved in an organic solvent. Upon injection of the DTG-containing solution, the polymer will solidify at the injection site to form the implant. Its potential advantage is that it does not require surgical removal. However, such devices require insertion by medical professionals and processing temperatures that are required during manufacture may result in ARV degradation. There is also the potential for dumping a large amount of drug from the biodegradable polymers. Moreover, the organic solvent used and the high viscosity of the gel could cause injection site reactions [43]. As the implant is biodegradable any need for removal is a challenge especially at longer times after insertion. These limitations could be overcome by refillable devices that do not require repeated surgical insertion or removal. Indeed, vaginal films and gels loaded with ARVs are also being developed [44, 45]. These facilitate sustained release of therapeutic drug for a year and are each replaceable.

Oral Formulations

Among all the mentioned strategies, nanosuspensions or solid drug nanoparticles provide advantage over others in terms of translation to industrial level production through spray dry manufacture. A single step emulsion was developed that employs a templated freeze-drying technique to produce nanosuspensions of efavirenz (EFV) [46]. Nanosuspensions of EFV exhibit reduced cytotoxicity and increased drug absorption in Caco-2 cells. *In vivo* analysis of these solid nanoparticles show improved drug PK (higher C_{max} , C_{min} and AUC) in rats compared to EFV. EFV nanosuspensions at a 300 mg dose could equal 600 mg EFV regimens [46]. Similar nanosuspensions show improved oral bioavailability for maraviroc

[47]. Oral formulations are of particular interest for pediatric patients. The current standard formulation of ritonavir (RTV)-boosted lopinavir (LPV) includes 42% ethanol relative to drug to solubilize LPV, which has poor aqueous solubility, and is undesirable for pediatric patients. Nanosuspensions of LPV produced by emulsion templated freeze-drying provided plasma drug concentrations similar to conventional LPV following oral administration [48]. Improvements for LPV formulations were made by anti-solvent precipitations followed by high pressure homogenization and step-wise freeze drying cycles [49]. These provide the potential for improved oral bioavailability over unformulated RTV-boosted LPV and demonstrate the potential elimination of RTV boosting [49].

Further modifications have been made by advanced film-coated gastro-resistant “Nanoparticle-in-Microparticle Oral Delivery System (NiMDS)” for the oral administration of darunavir/RTV (DRV/r) combinations [50]. This system can overcome the limitations of protease inhibitors, including poor water solubility at intestinal pH and greater gastric solubility. NiMDS are pure nanoparticles of DRV/r encapsulated within film-coated microparticles. DRV and RTV nanoparticles are synthesized by sequential nanoprecipitation/solvent diffusion and evaporation, employing sodium alginate as a stabilizer and then encapsulated within calcium alginate/chitosan. A series of polymethacrylate copolymers with differential solubilities in the gastrointestinal tract film-coat the particles. The microparticles ensure stability under gastric-like pH. PK analysis in rodents showed that DRV/r-loaded NiMDS increased the oral bioavailability of DRV by 2.3-fold. The approach highlights NiMDS for improving oral PK [50]. Recently, a novel gastric resistant oral dosage was developed with an elastomeric core attached to six arms composed of rigid structural polymer [51]. These rigid arms serve as carriers for the drugpolymer matrices which can achieve constant and sustained plasma DTG, RPV and CAB concentrations for up to one week. However, product complexity and dosing remain a major hurdle for development.

Coformulations

Coformulation of multiple ARVs has drawn growing interest in recent years [14, 52–56]. Packaging of multiple ARVs into a single dosage form could potentially improve targeting of different viral replication cycle stages and as such minimize viral resistance. In addition, co-delivery of long acting multiple ARVs could improve patient adherence. Most recently, the development of multidrug lipid nanoparticles encapsulating atazanavir (ATV), RTV and tenofovir (TFV) was reported [56]. These nanoparticles were fabricated by dissolving lipids in chloroform and ethanol followed by drying, rehydration and homogenization with drug suspensions. While development of multiple agent based long acting formulations could simplify timing of dosing schedules, combinations of compounds within a single lipid nanoparticle introduces challenges, including use of organic solvents during processing and increased potential for drug-drug interactions, limited lipid stability and reduced ability to independently control drug release. Lipid-based drug combination was developed [53–56]. Investigators evaluated the PK profile of RTV-boosted ATV (ATV/r) and TFV lipid particles in non-human primates following a single subcutaneous injection and compared the PK profile to that of free drug and lipid-stabilized formulations of LPV/r and TFV [56]. After a single subcutaneous administration of the ATV, RTV, and TFV particles drug concentrations were sustained for 14 days whereas native drugs were detected for only 1 to 2 days. Lymph

node mononuclear cells showed significant levels for all 3 drugs by week 1 in lipid particle-treated animals. While the platform for combination therapy is an advance the dosing intervals remain a limitation [56]. Nonetheless, lipid ARV particles do provide sustained release and improved PK drug profiles irrespective of their hydrophobic or hydrophilic properties [54, 55].

From NanoART to LASER ART

Sequential steps are notable in the development of LA ART. The first was procurement of specific hydrophobic ARVs and then encasing them into particles that were later homogenized to optimize size and shape. The next was attachment of targeting systems to the particle surface that would facilitate depot formation and viral cell targets. Indeed, the potential of targeted nanoformulated ART (nanoART) to improve biodistribution and extend the half-life of hydrophobic ARVs from days to weeks was shown following intramuscular administration in rodents and non-human primates [57, 58]. Targeted delivery of ARVs to CD4⁺ T cells and macrophages has potential in the treatment of HIV-1 infection, as these cells are the primary targets for HIV. This can be achieved by attachment of specific peptides or proteins on the surface of the delivery systems, thereby maximizing binding and interactions between receptors expressed on target cells and delivery systems. Cell targeted nanomedicines could offer enhanced efficacy, reduced side effects, increased drug stability and effective subcellular targeting [13, 58]. Our own laboratory has developed injectable nanoformulations for different ARVs to facilitate monocyte-macrophage targeting [13, 58]. Folic acid (FA) was used as a targeting ligand to deliver drugs to monocyte-macrophages. FA was covalently conjugated onto poloxamers and used to manufacture nanosuspensions of the ARVs by high-pressure homogenization [13, 58]. FA-conjugated poloxamer-407 (P407), a biocompatible poloxamer surfactant, was used to form drug nanocrystals containing ATV/r [13]. The FA coated ATV nanoparticles (referred to as FA nanoATV) significantly enhanced drug uptake, retention and antiretroviral activities. No cellular toxicity was observed. Enhanced retentions of FA-nanoATV within recycling macrophage endosomes was observed, which confirmed the stable subcellular drug depot. PK evaluation in mice showed that a single intramuscular injection of FA-nanoATV/r enhanced ATV plasma concentration. Moreover, the ATV concentration in lymph nodes was increased nearly 4-fold and in liver and kidneys by up to 5-fold [13]. Furthermore, enhanced viral suppression was observed in human peripheral blood lymphocyte-reconstituted HIV-1_{ADA} infected *NOD. Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ* mice treated with FA-nanoATV/r compared to mice treated with untargeted nanoATV/r [58]. The development of anti-CD4 modified liposomes loaded with two ARVs, nevirapine and saquinavir, has also been described [59]. The prepared liposomes were made by thin film hydration and covalently linked to a CD4 antibody demonstrating improved cellular drug uptake and antiretroviral activity compared to native drugs. However, regardless of the targeting efficiencies the complexities of manufacture limited their development.

Other limitations of nanoART include rapid ARV metabolism and limited biodistribution [12, 13, 57, 58, 60–66]. These can be overcome through chemical modifications of native ARVs to generate lipophilic and hydrophobic prodrugs into long-acting slow effective release antiretroviral therapy (LASER ART) nanocrystals. The true advantages of LASER

ART is in permitting rapid drug penetration across physiological barriers, slow drug dissolution, poor water solubility, enhanced bioavailability and reduced systemic toxicities [17, 18, 24, 67]. LASER ART is defined as hydrophobic prodrug crystals stabilized by lipids enabling sustained release of therapeutic drug concentrations in plasma and transfer across anatomical viral reservoirs [15]. The inactive LASER ART prodrug is metabolized into the native active drug by enzymatic or chemical hydrolysis of the ester “masking group” to produce the active native drug. Prodrugs are a major component of LASER ART and enable loading of > 80% with improved membrane permeability [68–70].

Ester prodrugs of 3TC, ABC, DTG and CAB were synthesized through myristoylation to generate M3TC, MABC, MDTG and MCAB. A DTG prodrug nanoformulation (NMDTG) was prepared by myristoyl ester modification [17]. NMDTG particles showed enhancements in macrophage drug uptake, prolonged retention and drug potency for up to one month. PK tests in Balb/cJ mice showed blood and tissue DTG levels at, or above, the protein-adjusted 90% inhibitory concentration (PA-IC₉₀) for up to 56 days after a single 45 mg/kg intramuscular injection. NMDTG injection of (118 mg/mL; 25.5 mg/kg DTG equivalents) to rhesus macaques resulted in plasma DTG levels of up to 86 and 28 ng/mL on days 35 and 91[21] without adverse events [17, 21]. Similarly, parenteral nanoformulated CAB prodrug administration of 45 mg/kg equivalents provided plasma drug levels above 4 times the PA-IC₉₀ (660 ng/mL) for 56 days in rhesus macaques and above the 1X PA-IC₉₀ (166 ng/ml) to 13 weeks in mice [18,22].

Novel formulations of ABC by PROdrug and nucleoTIDE (ProTide) technology (NM3ABC) were produced [19]. Three (NM1ABC, NM2ABC, NM3ABC) were made. Among these, M3ABC, showed the highest particle encasement efficiency, produced the highest intracellular carbovir-triphosphate (CBV-TP) levels and formed a long-lived cell-based depot. CBV-TP levels for seen for extended time periods in lymphocytes [19]. While LASER ART can extend drug interval dosing it may supplant other available options considering any limitations in adverse events, injection volumes, ease of distribution and PK parameters (Figure 1). All together, these data demonstrate that thoughtfully engineered prodrugs can improve PK and ARV biodistributions over encapsulation of native drug.

Pharmacokinetic (PK) Modeling

Models are sometimes used to predict PK after dosing in animals and humans. These define timed correlations between relevant tissue and plasma drug concentrations. PK can be predicted by incorporating physicochemical properties and *in vivo* behavior of drug molecules in the design of such mathematical representations [71]. Physiologically based pharmacokinetic (PBPK) models are based on the anatomical individual tissue compartments and drug movement and used as tool for predicting PK and biodistribution of drug molecules [72, 73]. Its limitations reside in a very complex *in vivo* distribution and drug transportation [74]. Nanoparticle size, shape and surface characteristics all affect nanoparticle distribution. While some nanoparticles are designed for uptake by the reticuloendothelial system, others are carried through the lymphatic system [75, 76]. The first nanoparticle experimentally-based PBPK was designed for doxorubicin-loaded liposomes [77]. Since then a number of nanomaterials were used to fit PBPK models to

predict biodistribution [78]. Recently such models were used to simulate the PK of long-acting antiretroviral drug formulations validated against clinical data for better prediction of drug dose optimization including release rates from the intramuscular injection depot [79]. PK predictions and dose optimizations for the antiretroviral drug EFV were developed with simulation and computational modeling [80]. Furthermore, the same approach was used to predict the PK of CAB LA and RPV LA formulations in adults and children by considering absorption, distribution, metabolism and drug excretion [81]. Despite the growing interest in modeling to predict nanoformulated ARV PK, there are huge challenges that restrict the application of PBPK modeling and simulation for human drug PK prediction. *First*, PBPK models require more clinical and *in vivo* experimental data when compared to traditional animal PK models [82]. *Second*, clinical variables abound and too many experimental parameters would be required to develop an ideal PBPK model, including predictability problems from *in vivo* animal to human clinical trial studies and data collection variability from person to person [83–85]. *Third*, routes of administration and absorption rates for nanoformulations, including transdermal, oral, intravenous, intramuscular and vaginal administration, are each unique in animals and humans and introduce ambiguity into PK parameters [86]. *Fourth*, lack of suitable data sets provide poor knowledge of physiologic conditions, biochemical changes and tissue-specific enzymes that may be seen in some patients. Moreover, variation in the number and type of drug transporters, type and species specificity of cell receptors, drug permeability, and enzyme activities can result in inaccurate predictions [84, 87]. Lastly, the PKs of highly hydrophobic drugs with different size and shape of nanoformulations are difficult to predict due to high drug protein binding and difficulty in mimicking the exact plasma environment [88]. Finally, such models may not be accurate with diverse chemical and physicochemical alterations associated with many of the advanced formulations [89]. Such limitations have given rise to the development of ARV theranostics.

Theranostics: ARV Particle Detection and Therapeutic Efficacy

Theranostics is an emerging discipline that uses agents that allow simultaneous measures of diagnoses with therapeutic deliverables. Biodegradable and biocompatible nanoparticles hold an important role in the theranostics field and allow us to combine diagnostic and therapeutic properties with desired cell and tissue targeting for a number of diseases (Figure 2). Since the last decade advances in surface chemistry of theranostic nanoparticles has enabled the development of more specific individualized therapies for various diseases. Theranostic particles can be made by encapsulating therapeutic drug into imaging nanoparticles such as iron oxide nanoparticles and gold nanoparticles or by tagging imaging probes including fluorescence dyes and radioisotopes onto the therapeutic nanoparticles. Encapsulating the imaging and therapeutic agents together in a biocompatible nanocarrier is also practical. Moreover, use of intrinsic imaging and therapeutic nanoparticles can predict drug potency. In general, theranostic nanoparticles provide combinations of organic and inorganic phase encasements allowing drug delivery by organic nanoparticles and bioimaging made possible by added inorganic components [90, 91].

The realization of theranostic particle use rests in its abilities to accurately measure drug distribution and predict PK profiles. In conjunction with radiolabel and fluorescence probe,

drug-loaded nanoparticles can allow PK and real-time drug distribution analyses. Biodistribution of drug-loaded particles depends upon drug properties including lipophilicity, extent of loading, encapsulation and hydrophobicity as well as particle size, shape, surface chemistry and the inherent cell and tissue physicochemical properties [15, 92]. Despite excellent therapeutic efficacy of LASER ART in suppressing viral load, assessment of viral reservoirs remains a significant challenge. To this end, theranostic particles can facilitate drug concentration measures in reservoir sites to assess drug depot formation. Superior spatial resolution afforded by noninvasive positron emission tomography, computed tomography, magnetic resonance imaging and single proton emission computed tomography imaging enable accurate real-time biodistribution studies of theranostic particles with high resolution and sensitivity. Recently, using organic-inorganic hybrids, we developed stable FA decorated europium (Eu^{3+}) doped cobalt ferrite (FA-EuCF) nanoparticles encapsulating lipophilic DTG. The decorated particles can be readily taken up by macrophages to establish a reticuloendothelial system drug depot and have similar biodistribution in Sprague Dawley rats and rhesus macaques [92]. Other multimodal ^{111}In radiolabeled EuCF-RPV theranostic particles have also proven to provide a reliable estimate of drug biodistribution [93]. Thus, multimodal theranostic nanoparticles are a promising tool in early disease diagnosis. While theranostic nanoparticles are thought limited to study of drugs with a long circulation half-life porphyrin nanoparticles allow more efficient targeting with subsequent activation of photodynamic activity to eliminate cancers or infected cells [94]. Studies performed with superparamagnetic iron oxide nanoparticles functionalized with gelatin-oleic acid show enhanced PK and targeted biodistribution of the nanoparticles [95].

Prodrugs are readily nanoformulated and cleaved to active moieties [20, 68, 96] with translational potential [97, 98], while limited, in part, by inherent complexities and scale ups [99–101]. ARV nanoparticles are endocytosed by macrophages and stored and trafficked in subcellular compartments [102–105]. Cell retention of drug contributes to its LA antiviral activity [103, 105, 106]. Nanomedicines traffic to acidic lysosomal compartments where low pH degrades the nanoformulation and releases active drug [107]. Attention to each of these limitations ensures proper evaluation and clinical translation.

Good laboratory and manufacturing practices (GLP and GMP)

There are inherent challenges in translating nanomedicines into clinical entities [108, 109]. Indeed, the structural and chemical complexity of nanomedicines can affect scale-up production, batch-to-batch reproducibility, formulation stability and sterilization [101, 110, 111]. With these hurdles in mind protocols for scale-up and formulation reproducibility were developed for LASER ART then tested in large animals for long-acting activity and toxicities [21, 22, 24]. GLP protocols ensured uniformity, consistency, reliability, reproducibility, quality, and integrity of pharmaceutical productsⁱⁱ. GMP scale-up production and product quality assessments follow ensuring product translation is performed from bench to bedside is a multistep, simple and interactive mannerⁱⁱⁱ (Figure 3).

ⁱⁱ. <http://www.gmppublications.com/Part58GLP.htm>

ⁱⁱⁱ. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=210>

Small animal model systems provide screening PK and pharmacodynamic (PD) assessments. In these systems optimizing product delivery, drug tissue targeting, metabolism, disease outcomes and potential toxicities can be addressed. For LASER ART immune-deficient mice reconstituted with human immune cells allow assessments of pre-exposure prophylaxis and antiviral responses [112–114]. However, large animals that include rhesus macaques need to be employed for confirmatory PK and PD tests [115–117] as species differences commonly occur in drug metabolism [118, 119].

Finally, to prepare nanoformulations for pre-clinical safety and Phase 1 clinical studies, the nanoformulation production, composition and stability must be optimized by GLP and GMP protocols and guidelines (Figure 3ⁱⁱⁱ) Producing sufficient quantities of nanomedicines for Phase 1 clinical studies requires GMP-validated and strict quality assurance measures. Immune and metabolic testing for safety and use of electron-beam or gamma irradiation for sterility help ensure the final nanomedicine product can meet the requirements of an investigational new drug application with completion of all United States Food and Drug Administration requirements. To achieve this goal for LA ARVs, we created our own Nebraska Nanomedicine Production Plant GLP and GMP facility. Like others it enables optimized scale-up of developed formulations and manufacturing of product for clinical testing.

Concluding Remarks and Future Perspectives

The realization of long acting prodrug ARV formulations from the laboratory to clinical use is as of now a challenge (see Outstanding Questions). To truly produce a superior product the long acting capabilities and the biological properties of the nanomedicines need be realized and must include an ability to cross cell membrane barriers and release drug cargo slowly at infectious sites. The potential viability of active targeting through engagement of cell receptors needs also to be determined in relevant cell and animal models. Active prodrug release from the nanoformulation in subcellular compartments and prodrug hydrolysis needs to be determined in relationship to any elicited changes to the cellular environment. For example, crystalline ARVs are taken up by macrophages by endocytosis and stored in endosomal compartments. Drug retention in endosomal compartments parallels the assembly of HIV virions and contributes to its long-acting antiviral activity. Other nanomedicines are trafficked to acidic lysosomal compartments where low pH degrades the nanocrystal and releases the active drug. Furthermore, potential toxicities can also be determined in these cell-based systems. Cell-specific uptake and activity and effectiveness against different strains must be screened as well. The key role of cell reservoirs and their interactions with ARV nanocrystals must be uncovered if such novel treatments can be realized (Figure 4).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Tatham LM et al. (2015) Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. *Ther Deliv* 6 (4), 469–90. [PubMed: 25996045]
2. Margolis DA et al. (2017) Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. *Lancet* 390 (10101), 1499–1510. [PubMed: 28750935]
3. Ferretti F and Boffito M (2018) Rilpivirine long-acting for the prevention and treatment of HIV infection. *Curr Opin HIV AIDS* 13 (4), 300–307. [PubMed: 29794818]
4. Williams PE et al. (2015) Formulation and pharmacology of long-acting rilpivirine. *Curr Opin HIV AIDS* 10 (4), 233–8. [PubMed: 26049947]
5. Spreen WR et al. (2013) Long-acting injectable antiretrovirals for HIV treatment and prevention. *Curr Opin HIV AIDS* 8 (6), 565–71. [PubMed: 24100877]
6. Williams J et al. (2013) Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. *Nanomedicine (Lond)* 8 (11), 1807–13. [PubMed: 23611617]
7. Landovitz RJ et al. (2018) Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. *PLoS Med* 15 (11), e1002690. [PubMed: 30408115]
8. Margolis DA et al. (2015) Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naïve adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. *Lancet Infect Dis* 15 (10), 1145–1155. [PubMed: 26201299]
9. Andrews CD et al. (2014) Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. *Science* 343 (6175), 1151–4. [PubMed: 24594934]
10. Balkundi S et al. (2011) Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. *Int J Nanomedicine* 6, 3393–404. [PubMed: 22267924]
11. Martinez-Skinner AL et al. (2015) Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. *PLoS One* 10 (12), e0145966. [PubMed: 26716700]
12. Nowacek AS et al. (2011) Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. *J Control Release* 150 (2), 204–11. [PubMed: 21108978]
13. Puligujja P et al. (2013) Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. *Nanomedicine* 9 (8), 1263–73.
14. Mandal S et al. (2018) Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. *J Control Release* 294, 216–225. [PubMed: 30576746]
15. Edagwa B et al. (2017) Long-acting slow effective release antiretroviral therapy. *Expert Opin Drug Deliv* 14 (11), 1281–1291. [PubMed: 28128004]
16. Guo D et al. (2016) Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. *J Acquir Immune Defic Syndr*, e75–e83.
17. Sillman B et al. (2018) Creation of a long-acting nanoformulated dolutegravir. *Nat Commun* 9 (1), 443. [PubMed: 29402886]
18. Zhou T et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. *Biomaterials* 151, 53–65. [PubMed: 29059541]
19. Lin Z et al. (2018) ProTide generated long-acting abacavir nanoformulations. *Chem Commun (Camb)* 54 (60), 8371–8374. [PubMed: 29995046]
20. Piplani M et al. (2016) Prodrugs of Antiinfective Agents: A Review. *J Pharm Pharm Sci* 19 (1), 82–113. [PubMed: 27096695]
21. McMillan J et al. (2017) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. *Antimicrob Agents Chemother* 62 (1), e01316–17. [PubMed: 29061742]

22. McMillan J et al. (2019) Pharmacokinetic testing of a first generation cabotegravir prodrug in rhesus macaques. *AIDS* 33 (3), 585–588. [PubMed: 30289818]
23. Singh D et al. (2016) Development and characterization of a long-acting nanoformulated abacavir prodrug. *Nanomedicine (Lond)* 11 (15), 1913–27. [PubMed: 27456759]
24. Zhou T et al. (2018) Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. *Nanomedicine (Lond)* 13 (8), 871–885. [PubMed: 29553879]
25. Trezza C et al. (2015) Formulation and pharmacology of long-acting cabotegravir. *Curr Opin HIV AIDS* 10 (4), 239–45. [PubMed: 26049948]
26. van 't Klooster G et al. (2010) Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. *Antimicrob Agents Chemother* 54 (5), 2042–50. [PubMed: 20160045]
27. Boyd MA and Cooper DA (2017) Long-acting injectable ART: next revolution in HIV? *Lancet* 390 (10101), 1468–1470. [PubMed: 28750936]
28. Markowitz M et al. (2017) Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. *Lancet HIV* 4 (8), e331–e340. [PubMed: 28546090]
29. Barrett SE et al. (2018) Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention. *Antimicrob Agents Chemother* 62 (10), e01058–18. [PubMed: 30012772]
30. Flexner C (2018) Antiretroviral implants for treatment and prevention of HIV infection. *Curr Opin HIV AIDS* 13 (4), 374–380. [PubMed: 29794816]
31. Gunawardana M et al. (2015) Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. *Antimicrob Agents Chemother* 59 (7), 3913–9. [PubMed: 25896688]
32. Markowitz M and Sarafianos SG (2018) 4'-Ethynyl-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. *Curr Opin HIV AIDS* 13 (4), 294–299. [PubMed: 29697468]
33. Vincent KL et al. (2018) Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. *PLoS Med* 15 (9), e1002655. [PubMed: 30265679]
34. Murphy DJ et al. (2014) Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. *J Antimicrob Chemother* 69 (9), 2477–88. [PubMed: 24862093]
35. Johnson TJ et al. (2010) Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. *Eur J Pharm Sci* 39 (4), 203–12. [PubMed: 19958831]
36. Fetherston SM et al. (2013) A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. *Eur J Pharm Sci* 48 (3), 406–15. [PubMed: 23266465]
37. Chen BA et al. (2018) Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women. *Clin Infect Dis*, doi: 10.1093/cid/ciy654.
38. Baeten JM et al. (2016) Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. *N Engl J Med* 375 (22), 2121–2132. [PubMed: 26900902]
39. Chen BA et al. (2015) Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. *J Acquir Immune Defic Syndr* 70 (3), 242–9. [PubMed: 26034880]
40. Robinson JA et al. (2017) Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). *AIDS Res Hum Retroviruses* 33 (4), 339–346. [PubMed: 27809557]
41. Devlin B et al. (2013) Development of dapivirine vaginal ring for HIV prevention. *Antiviral Res* 100 Suppl, S3–8. [PubMed: 24188702]
42. Kovarova M et al. (2018) Ultra-long-acting removable drug delivery system for HIV treatment and prevention. *Nat Commun* 9 (1), 4156. [PubMed: 30297889]

43. Kranz H et al. (2001) Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. *Int J Pharm* 212 (1), 11–8. [PubMed: 11165816]
44. Traore YL et al. (2018) Dynamic mechanical behaviour of nanoparticle loaded biodegradable PVA films for vaginal drug delivery. *J Biomater Appl* 32 (8), 1119–1126. [PubMed: 29105543]
45. Agashe H et al. (2012) Formulation and delivery of microbicides. *Curr HIV Res* 10 (1), 88–96. [PubMed: 22264050]
46. McDonald TO et al. (2014) Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. *Adv Healthc Mater* 3 (3), 400–11. [PubMed: 23997027]
47. Savage AC et al. (2018) Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. *Eur J Pharm Biopharm*, doi: 10.1016/j.ejpb.2018.05.015.
48. Giardiello M et al. (2016) Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. *Nat Commun* 7, 13184. [PubMed: 27767027]
49. Jain S et al. (2013) Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. *Nanomedicine (Lond)* 8 (10), 1639–55. [PubMed: 23351133]
50. Augustine R et al. (2018) Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination. *Acta Biomater* 74, 344–359. [PubMed: 29723705]
51. Kirtane AR et al. (2018) Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. *Nat Commun* 9 (1), 2. [PubMed: 29317618]
52. Sun HY et al. (2018) Dolutegravir-rilpivirine coformulation. *Curr Opin HIV AIDS* 13 (4), 320–325. [PubMed: 29553948]
53. Gao Y et al. (2018) Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy. *Eur J Pharm Biopharm*, doi: 10.1016/j.ejpb.2018.04.014.
54. Koehn J et al. (2018) Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates. *AIDS* 32 (17), 2463–2467. [PubMed: 30102655]
55. McConnachie LA et al. (2018) Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. *J Pharm Sci* 107 (7), 1787–1790. [PubMed: 29548975]
56. Perazzolo S et al. (2018) Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates. *J Pharm Sci* 107 (12), 3153–3162. [PubMed: 30121315]
57. Gautam N et al. (2014) Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations. *Antimicrob Agents Chemother* 58 (12), 7510–9. [PubMed: 25288084]
58. Puligujja P et al. (2015) Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. *Biomaterials* 41, 141–50. [PubMed: 25522973]
59. Ramana LN et al. (2015) Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV. *Eur J Pharm Biopharm* 89, 300–11. [PubMed: 25500283]
60. McMillan JM et al. (2018) Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice. *J Pharmacol Exp Ther* 365 (2), 272–280. [PubMed: 29476044]
61. Nowacek AS et al. (2010) Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. *J Neuroimmune Pharmacol* 5 (4), 592–601. [PubMed: 20237859]
62. Nowacek AS et al. (2009) NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. *Nanomedicine (Lond)* 4 (8), 903–17. [PubMed: 19958227]
63. Gautam N et al. (2018) Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS. *J Pharm Biomed Anal* 153, 248–259. [PubMed: 29518644]

64. Gautam N et al. (2013) Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. *Antimicrob Agents Chemother* 57 (7), 3110–20. [PubMed: 23612193]
65. Dash PK et al. (2012) Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. *Aids* 26 (17), 2135–44. [PubMed: 22824628]
66. Roy U et al. (2012) Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. *J Infect Dis* 206 (10), 1577–88. [PubMed: 22811299]
67. Montenegro-Burke JR et al. (2018) Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress. *Mol Neurobiol*, doi: 10.1007/s12035-018-1273-8.
68. Rautio J et al. (2018) The expanding role of prodrugs in contemporary drug design and development. *Nat Rev Drug Discov* 17 (8), 559–587. [PubMed: 29700501]
69. Rautio J et al. (2008) Prodrugs: design and clinical applications. *Nat Rev Drug Discov* 7 (3), 255–70. [PubMed: 18219308]
70. Huttunen KM and Rautio J (2011) Prodrugs - an efficient way to breach delivery and targeting barriers. *Curr Top Med Chem* 11 (18), 2265–87. [PubMed: 21671868]
71. Jones HM et al. (2013) Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. *AAPS J* 15 (2), 377–87. [PubMed: 23269526]
72. Zhuang X and Lu C (2016) PBPK modeling and simulation in drug research and development. *Acta Pharm Sin B* 6 (5), 430–440. [PubMed: 27909650]
73. Gilkey MJ et al. (2015) Physiologically Based Pharmacokinetic Modeling of Fluorescently Labeled Block Copolymer Nanoparticles for Controlled Drug Delivery in Leukemia Therapy. *CPT Pharmacometrics Syst Pharmacol* 4 (3), e00013. [PubMed: 26225236]
74. Li M et al. (2017) Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles. *AAPS J* 19 (1), 26–42. [PubMed: 27834047]
75. Blanco E et al. (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol* 33 (9), 941–51. [PubMed: 26348965]
76. Chou LY and Chan WC (2012) Fluorescence-tagged gold nanoparticles for rapidly characterizing the size-dependent biodistribution in tumor models. *Adv Healthc Mater* 1 (6), 714–21. [PubMed: 23184822]
77. Harashima H and Kiwada H (1999) The Pharmacokinetics of Liposomes in Tumor Targeting. *Adv Drug Deliv Rev* 40 (1–2), 1–2. [PubMed: 10837776]
78. Li D et al. (2014) Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats. *Nanotoxicology* 8 Suppl 1, 128–37. [PubMed: 24392664]
79. Rajoli RK et al. (2015) Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. *Clin Pharmacokinet* 54 (6), 639–50. [PubMed: 25523214]
80. Siccardi M et al. (2016) Validation of Computational Approaches for Antiretroviral Dose Optimization. *Antimicrob Agents Chemother* 60 (6), 3838–9. [PubMed: 27044544]
81. Rajoli RKR et al. (2018) Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling. *J Infect Dis*, doi: 10.1093/infdis/jiy726.
82. Caldwell JC et al. (2012) Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms. *J Toxicol* 2012, 852384. [PubMed: 22899915]
83. Jones HM et al. (2015) Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. *Clin Pharmacol Ther* 97 (3), 247–62. [PubMed: 25670209]
84. Edginton AN and Joshi G (2011) Have physiologically-based pharmacokinetic models delivered? *Expert Opin Drug Metab Toxicol* 7 (8), 929–34. [PubMed: 21762039]
85. Poulin P and Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. *J Pharm Sci* 89 (1), 16–35. [PubMed: 10664535]

86. Kay K et al. (2018) Physiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations. *Br J Clin Pharmacol* 84 (9), 1950–1969. [PubMed: 29714824]
87. Harwood MD et al. (2013) Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. *Biopharm Drug Dispos* 34 (1), 2–28. [PubMed: 22927116]
88. Ye M et al. (2016) A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding. *Biopharm Drug Dispos* 37 (3), 123–41. [PubMed: 26531057]
89. Siccaldi M et al. (2018) The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. *Adv Drug Deliv Rev* 131, 116–121. [PubMed: 29959958]
90. Park KE et al. (2017) Hyaluronic acid-coated nanoparticles for targeted photodynamic therapy of cancer guided by near-infrared and MR imaging. *Carbohydr Polym* 157, 476–483. [PubMed: 27987951]
91. Chen F et al. (2014) Theranostic nanoparticles. *J Nucl Med* 55 (12), 1919–22. [PubMed: 25413134]
92. Kevadiya BD et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. *Theranostics* 8 (1), 256–276. [PubMed: 29290806]
93. Ottemann BM et al. (2018) Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. *Biomaterials* 185, 174–193. [PubMed: 30245386]
94. Jin Y (2014) Multifunctional compact hybrid Au nanoshells: a new generation of nanoplasmonic probes for biosensing, imaging, and controlled release. *Acc Chem Res* 47 (1), 138–48. [PubMed: 23992824]
95. Tran TT et al. (2017) Biodistribution and in vivo performance of fattigation-platform theranostic nanoparticles. *Mater Sci Eng C Mater Biol Appl* 79, 671–678. [PubMed: 28629067]
96. Gotham D et al. (2017) Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide. *Curr Opin HIV AIDS* 12 (4), 324–333. [PubMed: 28403027]
97. Hassanzadeh P et al. (2018) Ignoring the modeling approaches: Towards the shadowy paths in nanomedicine. *J Control Release* 280, 58–75. [PubMed: 29723612]
98. Mu Q et al. (2018) Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. *J Drug Target* 26 (5–6), 435–447. [PubMed: 29285948]
99. Satakar P et al. (2016) Challenges of clinical translation in nanomedicine: A qualitative study. *Nanomedicine* 12 (4), 893–900. [PubMed: 26772431]
100. Lammers T et al. (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. *J Control Release* 161 (2), 175–87. [PubMed: 21945285]
101. Sainz V et al. (2015) Regulatory aspects on nanomedicines. *Biochem Biophys Res Commun* 468 (3), 504–10. [PubMed: 26260323]
102. Martinez-Skinner AL et al. (2013) Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity. *J Proteome Res* 12 (5), 2282–94. [PubMed: 23544708]
103. Arainga M et al. (2015) Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages. *Retrovirology* 12, 5. [PubMed: 25608975]
104. Guo D et al. (2014) Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. *J Virol* 88 (17), 9504–13. [PubMed: 24920821]
105. Gnanadhas DP et al. (2017) Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. *J Clin Invest* 127 (3), 857–873. [PubMed: 28134625]
106. Arainga M et al. (2016) HIV-1 cellular and tissue replication patterns in infected humanized mice. *Sci Rep* 6, 23513. [PubMed: 26996968]
107. McMillan J et al. (2011) Cell delivery of therapeutic nanoparticles. *Prog Mol Biol Transl Sci* 104, 563–601. [PubMed: 22093229]

108. Hare JJ et al. (2017) Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. *Adv Drug Deliv Rev* 108, 25–38. [PubMed: 27137110]
109. Hua S et al. (2018) Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. *Front Pharmacol* 9, 790. [PubMed: 30065653]
110. Svenson S (2012) Clinical translation of nanomedicines. *Curr Opin Solid State Mater Sci* 16, 287–294.
111. Narang AS et al. (2013) Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. *J Pharm Sci* 102 (11), 3867–82. [PubMed: 24037829]
112. Marsden MD and Zack JA (2017) Humanized Mouse Models for Human Immunodeficiency Virus Infection. *Annu Rev Virol* 4 (1), 393–412. [PubMed: 28746819]
113. Deruaz M and Tager AM (2017) Humanized mouse models of latent HIV infection. *Curr Opin Virol* 25, 97–104. [PubMed: 28810166]
114. Gorantla S et al. (2012) Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders? *J Neuroimmune Pharmacol* 7 (2), 352–62. [PubMed: 22222956]
115. Garcia-Tellez T et al. (2016) Non-human primates in HIV research: Achievements, limits and alternatives. *Infect Genet Evol* 46, 324–332. [PubMed: 27469027]
116. Desai M et al. (2017) Recent advances in pre-exposure prophylaxis for HIV. *BMJ* 359, j5011. [PubMed: 29229609]
117. Mallard J and Williams K (2018) An SIV macaque model of SIV and HAND: the need for adjunctive therapies in HIV that target activated monocytes and macrophages. *J Neurovirol* 24 (2), 213–219. [PubMed: 29435829]
118. Toutain PL et al. (2010) Species differences in pharmacokinetics and pharmacodynamics. *Handb Exp Pharmacol* (199), 19–48. [PubMed: 20204582]
119. Haley PJ (2017) The lymphoid system: a review of species differences. *J Toxicol Pathol* 30 (2), 111–123. [PubMed: 28458449]

Highlights

Long acting parenteral antiretroviral drugs (ARVs) can improve regimen adherence, limit toxicities and reduce viral resistance.

Prodrug ARV formulations increase the apparent half-life and facilitate drug entry and retention into infectious reservoirs.

Long acting slow effective release antiretroviral therapies (LASER ART) are hydrophobic lipophilic ARV nanocrystals with a defined 200 to 400 nm size.

Controlled prodrug release and slowed hydrolysis can prolong half-life, improve pharmacokinetic profiles and facilitate native ARV tissue biodistribution.

LASER ART can lower viral transmission rates, improve treatment outcomes and facilitate pre-exposure prophylaxis regimens in virus-infected or susceptible individuals.

Scale up by good laboratory and manufacturing practices facilitates LASER ART translation.

Figure 1.

Generating long-acting slow effective release antiretroviral therapy (LASER ART). The plates serve to review each of the delivery schemes now either developed or being actively researched for oral, device-linked or parenteral administrations. (A) Schematic illustration of nanoformulated native drug (nanoART) or long acting slow effective release ART (LASER ART) as defined by hydrophobic lipophilic prodrugs. Nanocrystals are developed of ARVs (for example, dolutegravir). Surfactant-stabilized nanocrystals are prepared by high-pressure homogenization or wet milling. Cell-based assays are used to screen drug potency,

cytotoxicity, uptake, retention, release and efficacy. The top performing formulations are then moved forward for safety, pharmacokinetic and pharmacodynamics assessments. (B) The prodrug concept and LASER ART nanocrystal formation, particle uptake, intracellular prodrug release and slow hydrolysis to extend the apparent half-life of the drug. The ARVs are modified to improve drug potency, enhance cell membrane permeability and facilitate encapsulation into LASER ART nanocrystals that are rapidly taken up by cells and distributed into lymphoid tissues. (C) Examples of extended release oral ARV formulations in preclinical development include capsules, tablets, thin films and suspensions. The ARVs are embedded in a matrix system that controls drug release. (D) pH sensitive microparticles and devices are being leveraged to control release of ART after oral administration. (E) Subcutaneous implantable devices, vaginal rings, films and gels loaded with ARVs are at various stages of preclinical development to provide sustained release of ART for HIV-1 treatment and prevention.

Figure 2.

Theranostic multimodal nanoparticles predict drug delivery to infectious tissue sites. (A) Theranostic particles are made with multifunctional capabilities for delivery to virus infected, inflamed or after organ injuries. The schematic illustration denoted the surface targeting and internal drug, nucleic acid and or imaging payloads that form the backbone of the nanoparticle. (B) Following parenteral injection biodistribution is seen in each of the listed tissues with preference in HIV-1 infected lymphoid organs, brain and the reticuloendothelial system but not excluding the kidney, bone, muscle, heart and skin amongst others. (C) The multifunctionality of the particles with metal, isotope and fluorescence encasements, particle distribution can be monitored by bioimaging. These include, but are not limited to, single photon emission computed tomography-computerized tomography (SPECT/CT), confocal microscopy and magnetic resonance imaging (MRI) “amongst others” to track biodistributions. (D) Diagnostic and therapeutic payloads contained within the theranostic particles reach their cell and tissue destinations at levels reflecting extent of disease, infection, inflammation or degeneration (in red) then ameliorate the disease process or restrict/eliminate infection. The bioimaging of the particles can then

define time, place and drug levels in real time enabling delivery the therapeutics that combat disease events. All together these methods provide real-time particle tracking, biodistribution and treatment of disease (in green).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 3.

Current good manufacturing practices (cGMP). The Nebraska Nanomedicine Production Plant (NNPP) reflects standards set forth by the USA Food and Drug Administration (FDA). The facility is compliant with cGMP guidelines. Formulation development involves standard protocols for preclinical screening, particle purification, a range of stability tests, optimization of nanoparticle production and in-depth characterizations. These are first conducted using good laboratory practices and defined cross observational protocols. When cGMP dictates FDA compliant product scale-up, lyophilization and sterilization. These lead to the production of therapies for human use in clinical trials.

Figure 4. Developmental testing of prodrug formulations.

Design for chemical modifications of native ARV is forged into go no go “clock” criteria. CAB is given as an example. CAB was first transformed into a lipophilic hydrophobic prodrug. The transformation was screened by prodrug hydrolysis with plasma esterases during timed-incubations. Assessment of half-maximal effective concentration or EC₅₀ reflective of drug potency was made for antiretroviral responses halfway between baseline and maximum based exposures. The native drug and prodrug with or without nanoencasements were tested for uptake, release, retention and antiretroviral activities in primary human CD4⁺ T cells and macrophages. Bioanalytical testing was conducted that included prodrug stability over time, temperature and pH. Measures of drug and prodrug levels inside and released from cells were performed. In the subsequent evaluation nanoformulated prodrug was subjected to PK testing and tissue biodistribution in rodents then followed by parallel assessments in rhesus macaques. This then proceeded to full GLP guideline testing for product use and considered by a complete drug toxicology profile evaluation as is the pre-clinical PD testing evaluations for pre-exposure prophylaxis. Ongoing works includes serial titrated viral exposure through vaginal or rectal routes. Investigational new drug enabling, FDA approval and GMP production will precede the first in human testing (phase I clinical trial).